Logotype for Gritstone bio Inc

Gritstone bio (GRTS.Q) investor relations material

Gritstone bio Q2 2024 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Gritstone bio Inc
Q2 2024 earnings summary13 Aug, 2024

Executive summary

  • Reported a net loss of $23.4 million for Q2 2024 and $63.8 million for the six months ended June 30, 2024, compared to net losses of $35.3 million and $69.2 million for the same periods in 2023.

  • Revenue for Q2 2024 was $0.9 million, primarily from grant agreements, down from $2.0 million in Q2 2023.

  • Research and development expenses decreased to $20.8 million in Q2 2024 from $31.0 million in Q2 2023, reflecting cost reductions and a workforce reduction.

  • Preliminary Phase 2 data for GRANITE suggest potential clinical benefit in front-line metastatic MSS-CRC, with mature PFS data expected in Q3 2024.

  • Cash, cash equivalents, and marketable securities totaled $55.7 million to $61.7 million as of June 30, 2024, expected to fund operations into Q4 2024.

Financial highlights

  • Q2 2024 total revenue was $0.9 million, down from $2.0 million in Q2 2023; six-month revenue was $2.7 million, down from $4.4 million year-over-year.

  • Net loss per share was $(0.16) for Q2 2024 and $(0.49) for the six months, compared to $(0.31) and $(0.60) for the same periods in 2023.

  • Operating expenses for Q2 2024 were $28.5 million, down from $37.7 million in Q2 2023; six-month operating expenses were $70.1 million, down from $74.9 million.

  • General and administrative expenses rose to $7.7 million for Q2 2024, up $1.0 million year-over-year, mainly from increased personnel and stock-based compensation.

  • Other income of $4.8 million in Q2 2024 was due to revaluation of common warrants issued in April 2024.

Outlook and guidance

  • Existing cash and investments are expected to fund operations into Q4 2024; additional capital is required to continue beyond that period.

  • If unable to raise funds or renegotiate loan terms, the company expects to be in default of its minimum liquidity requirement in Q4 2024.

  • Management anticipates continued operating losses and negative cash flows for the foreseeable future.

  • Mature PFS data for GRANITE in MSS-CRC expected in Q3 2024.

  • Updates on the head-to-head Phase 2b study of the next-generation COVID-19 vaccine (CORAL) to be provided as available.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Gritstone bio Inc. is a biotechnology company that develops immunotherapies aimed at treating cancer and infectious diseases. The company leverages its expertise in genomics, machine learning, and immune system biology to create therapeutic vaccines and antibody-based treatments. Gritstone bio focuses on advancing precision medicine through innovative platforms designed to stimulate the immune system to recognize and combat specific disease targets. The company is headquartered in Emeryville, California, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage